Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 10/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.76 |
| ▸ | TSHR | P16473 | 3/20 | 0.76 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | USP2 | O75604 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1426593 | 0.89 | CYP2D6 (0.84) | CYP2D6CYP3A4TSHRSIGMAR1CYP2C19 | |
| Hydrochloric Acid SCHEMBL3013775 | 0.88 | CYP2D6 (0.82) | CYP2D6CYP3A4TSHRSIGMAR1CYP2C19 | |
| SCHEMBL1509461 | 0.87 | CYP2D6 (0.89) | CYP2D6CYP3A4TSHRCYP2C19ALDH1A1 | |
| SCHEMBL17609032 | 0.87 | CYP2D6 (0.84) | CYP2D6CYP3A4TSHRCYP2C19ALDH1A1 | |
| Hydrochloric Acid SCHEMBL17608851 | 0.85 | CYP2D6 (0.87) | CYP2D6CYP3A4TSHRCYP2C19ALDH1A1 | |
| SCHEMBL1426377 | 0.84 | CYP2D6 (0.67) | CYP2D6CYP3A4TSHRSIGMAR1CYP2C19 | |
| SCHEMBL4292159 | 0.84 | CYP2D6 (0.76) | CYP2D6CYP3A4TSHRSIGMAR1CYP2C19 | |
| SCHEMBL1732446 | 0.80 | CYP2D6 (0.65) | CYP2D6CYP3A4TSHRSIGMAR1CYP2C19 | |
| SCHEMBL15985246 | 0.80 | CYP2D6 (0.60) | CYP2D6CYP3A4TSHRSIGMAR1CYP2C19 | |
| SCHEMBL4130505 | 0.79 | TSHR (0.82) | CYP2D6CYP3A4TSHRSIGMAR1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9586961-B2 | Homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof | LEO PHARMA A/S (DK) | 2017-03-07 | — | — | US | disclosed |
| US-9586961-B2 | Homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof | LEO PHARMA A/S (DK) | 2017-03-07 | — | — | US | disclosed |
| EP-2590981-B1 | NOVEL HOMOPIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA AS (DK) | 2014-09-03 | — | — | EP | disclosed |
| EP-2590981-B1 | NOVEL HOMOPIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA AS (DK) | 2014-09-03 | — | — | EP | disclosed |
| US-20130172325-A1 | NOVEL HOMOPIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA A/S (DK) | 2013-07-04 | — | — | US | disclosed |
| US-20130172325-A1 | NOVEL HOMOPIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA A/S (DK) | 2013-07-04 | — | — | US | disclosed |
| US-20130172325-A1 | NOVEL HOMOPIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA A/S (DK) | 2013-07-04 | — | — | US | disclosed |
| EP-2590981-A1 | NOVEL HOMOPIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | Leo Pharma A/S (DK) | 2013-05-15 | — | — | EP | disclosed |
| WO-2012003829-A1 | NOVEL HOMOPIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA A/S (DK) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012003829-A1 | NOVEL HOMOPIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA A/S (DK) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172325-A1 | NOVEL HOMOPIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | JAK1, JAK2, JAK3 | CYP2D6 1638/4885CYP3A4 1139/4885TSHR 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.